Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy.

"Declarations Ethics approval and consent to participateThe Institutional Review Board at Hamamatsu University School of Medicine approved this study (No. 22-033). The study complied with approved guidelines. All analyses complied with the ethical standards of the Declaration of Helsinki. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines [45]. Consent for publicationPatient approval and written informed consent were waived because this study was based on reviews of patient records. All patients’ records and information were anonymized and de-identified prior to analysis. The information about the study was notified on the website (https://www.hama-med.ac.jp/research/22-033_1.pdf) to provide the patients or their legal representative an opportunity to refuse participation in the study (opt-out). Competing interestsThe authors have no relevant financial or non-financial interests to disclose. Competing interests The authors have no relevant financial or non-financial interests to disclose."

"Funding None."